FreshPatents.com Logo
Enter keywords:  

Track companies' patents here: Public Companies RSS Feeds | RSS Feed Home Page
Popular terms

[SEARCH]

G Protein topics
Antibodies
Nucleic Acid
G Proteins
Nucleic Acids
Amino Acid
Polypeptide
Protein A Affinity Chromatography
Chromatography
Chromatograph
Liver Metastasis
Membrane Protein
Colorectal Carcinoma
Rectal Carcinoma
Prophylactic
Glycoprotein

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

G Protein patents



      
           
This page is updated frequently with new G Protein-related patent applications. Subscribe to the G Protein RSS feed to automatically get the update: related G RSS feeds. RSS updates for this page: G Protein RSS RSS


Deimmunized serum-binding domains and their use in extending serum half-life

Macrogenics

Deimmunized serum-binding domains and their use in extending serum half-life

Deimmunized serum-binding domains and their use in extending serum half-life

Regeneron Pharmaceuticals

Human lambda light chain mice

Date/App# patent app List of recent G Protein-related patents
06/25/15
20150177240
 Nogo receptor binding protein patent thumbnailnew patent Nogo receptor binding protein
The invention provides sp35 polypeptides and fusion proteins thereof, sp35 antibodies and antigen-binding fragments thereof and nucleic acids encoding the same. The invention also provides compositions comprising, and methods for making and using, such sp35 antibodies, antigen-binding fragments thereof, sp35 polypeptides and fusion proteins thereof..
Biogen Idec Ma Inc.
06/25/15
20150176002
 Human lambda light chain mice patent thumbnailnew patent Human lambda light chain mice
Genetically modified mice are provided that express human λ variable (hvλ) sequences, including mice that express hvλ sequences from an endogenous mouse λ light chain locus, mice that express hvλ sequences from an endogenous mouse κ light chain locus, and mice that express hvλ sequences from a transgene or an episome wherein the hvλ sequence is linked to a mouse constant sequence. Mice are provided that are a source of somatically mutated human λ variable sequences useful for making antigen-binding proteins.
Regeneron Pharmaceuticals, Inc.
06/25/15
20150175697
 Deimmunized serum-binding domains and their use in extending serum half-life patent thumbnailnew patent Deimmunized serum-binding domains and their use in extending serum half-life
The present invention is directed to a polypeptide (for example, an antigen-binding molecule) that comprises a polypeptide portion of a deimmunized serum-binding protein capable of binding to said serum protein. The presence of the serum-binding protein extends the serum half-life of the polypeptide, relative to the serum half-life of the polypeptide if lacking the polypeptide portion of the deimmunized serum-binding protein.
Macrogenics, Inc.
06/25/15
20150175670
 Fusion proteins and combination vaccines comprising haemophilus influenzae protein e and pilin a patent thumbnailnew patent Fusion proteins and combination vaccines comprising haemophilus influenzae protein e and pilin a
The present invention relates to compositions comprising haemophilus influenzae protein e and pilin a. More particularly, the present application relates to fusion proteins and immunogenic compositions comprising protein e and pila, vaccines comprising such immunogenic compositions and therapeutic uses of the same..
Glaxosmithkline Biologicals S.a.
06/25/15
20150175661
 Gpcr with improved cell surface expression patent thumbnailnew patent Gpcr with improved cell surface expression
The present invention surprisingly shows that the addition of a heterologous viral-gpcr (g protein-coupled receptor) derived sequence at the amino terminal end of gpcrs improves cell surface expression of such receptors in eukaryotic cells. Transfected cells expressing the above heterologous viral gpcrs on their surface are useful for cell based assays to identify test compounds that increases or modulate activity of a gpcr or a ligand of a gpcr for example for drug discovery, development of novel flavors in the food industry or development of sensors based on odor gpcrs.
Canvax Biotech S.l
06/25/15
20150175658
 Induction of tumor immunity by variants of folate binding protein patent thumbnailnew patent Induction of tumor immunity by variants of folate binding protein
The present invention is directed to variants of antigens comprising folate binding protein epitopes as a composition associated with providing immunity against a tumor in an individual. The variant is effective in inducing cytotoxic t-lymphocytes but preferably not to the extent that they become sensitive to silencing by elimination, such as by apoptosis, or by anergy, as in unresponsiveness..
The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc.
06/25/15
20150174265
 Reversible masking of pore-forming proteins for macromolecular delivery patent thumbnailnew patent Reversible masking of pore-forming proteins for macromolecular delivery
The present invention features compositions and methods for enhancing endosomal escape of therapeutic agents in the cytoplasm of a cell to thereby provide more effective therapy. The endocytic pathway is the major uptake mechanism of cells, and biological agents such as proteins, dna, and sirna become entrapped in endosomes and subsequently degraded by lysosomal enzymes.
Massachusetts Institute Of Technology
06/25/15
20150174198
 Gene transfer into airway epithelial stem cell by using lentiviral vector pseudotyped with rna virus or dna virus spike protein patent thumbnailnew patent Gene transfer into airway epithelial stem cell by using lentiviral vector pseudotyped with rna virus or dna virus spike protein
The present inventors successfully introduced genes into stem cells of airway epithelial tissues using simian immunodeficiency virus vectors pseudotyped with f and hn, which are envelope glycoproteins of sendai virus. Gene transfer into airway epithelial tissue stem cells using a vector of the present invention is useful for gene therapy of genetic respiratory diseases such as cystic fibrosis.
Dnavec Corporation
06/25/15
20150173333
 Rapid specific pathogen free animal patent thumbnailnew patent Rapid specific pathogen free animal
A method of producing at least one specific pathogen free (spf) non-human animal and/or a method of producing at least one specific pathogen resistant (spr) non-human animal, the method comprising administration of a fusion protein to the surviving animal wherein the fusion protein comprises at least one polypeptide b which is a type 1 ribosome inactivating protein (rip) or fragment thereof; and (i) at least one polypeptide a which is an antimicrobial peptide; and/or (ii) at least one polypeptide c which is a cationic antimicrobial peptide (cap) or fragment thereof.. .
Biovalence Sdn. Bhd.
06/25/15
20150173332
 Human lambda light chain mice patent thumbnailnew patent Human lambda light chain mice
Genetically modified mice are provided that express human λ variable (hvλ) sequences, including mice that express hvλ sequences from an endogenous mouse λ light chain locus, mice that express hvλ sequences from an endogenous mouse κ light chain locus, and mice that express hvλ sequences from a transgene or an episome wherein the hvλ sequence is linked to a mouse constant sequence. Mice are provided that are a source of somatically mutated human λ variable sequences useful for making antigen-binding proteins.
Regeneron Pharmaceuticals, Inc.
06/25/15
20150173331
new patent

Human lambda light chain mice


Genetically modified mice are provided that express human λ variable (hvλ) sequences, including mice that express hvλ sequences from an endogenous mouse λ light chain locus, mice that express hvλ sequences from an endogenous mouse κ light chain locus, and mice that express hvλ sequences from a transgene or an episome wherein the hvλ sequence is linked to a mouse constant sequence. Mice are provided that are a source of somatically mutated human λ variable sequences useful for making antigen-binding proteins.
Regeneron Pharmaceuticals, Inc.
06/18/15
20150167019

Methods and products for transfecting cells


The present invention relates in part to nucleic acids encoding proteins, nucleic acids containing non-canonical nucleotides, therapeutics comprising nucleic acids, methods, kits, and devices for inducing cells to express proteins, methods, kits, and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, and therapeutics produced using these methods, kits, and devices. Methods for inducing cells to express proteins and for reprogramming and gene-editing cells using rna are disclosed.
Factor Bioscience Inc.
06/18/15
20150166985

Methods for correcting von willebrand factor point mutations


Some aspects of this disclosure provide strategies, systems, reagents, methods, and kits that are useful for the targeted editing of nucleic acids, including editing a nucleic acid encoding a mutant von willebrand factor protein to correct a point mutation associated with a disease or disorder, e.g., with von willebrand disease. The methods provided are useful for correcting a vwf point mutation within the genome of a cell or subject, e.g., within the human genome.
President And Fellows Of Harvard College
06/18/15
20150166984

Methods for correcting alpha-antitrypsin point mutations


Some aspects of this disclosure provide strategies, systems, reagents, methods, and kits that are useful for the targeted editing of nucleic acids, including editing a nucleic acid encoding a mutant α-antitrypsin protein to correct a point mutation associated with a disease or disorder, e.g., with chronic obstructive pulmonary disease (copd) disease. The methods provided are useful for correcting an α-antitrypsin point mutation within the genome of a cell or subject, e.g., within the human genome.
President And Fellows Of Harvard College
06/18/15
20150166983

Methods for correcting presenilin point mutations


Some aspects of this disclosure provide strategies, systems, reagents, methods, and kits that are useful for the targeted editing of nucleic acids, including editing a nucleic acid encoding a mutant presenilin1 protein to correct a point mutation associated with a disease or disorder, e.g., with familial alzheimer's disease. The methods provided are useful for correcting a psen1 point mutation within the genome of a cell or subject, e.g., within the human genome.
President And Fellows Of Harvard College
06/18/15
20150166982

Methods for correcting pi3k point mutations


Some aspects of this disclosure provide strategies, systems, reagents, methods, and kits that are useful for the targeted editing of nucleic acids, including editing a nucleic acid encoding a mutant pi3kca protein to correct a point mutation associated with a disease or disorder, e.g., with a neoplastic disorder. The methods provided are useful for correcting a pi3kca point mutation within the genome of a cell or subject, e.g., within the human genome.
President And Fellows Of Harvard College
06/18/15
20150166981

Methods for nucleic acid editing


Some aspects of this disclosure provide strategies, systems, reagents, methods, and kits that are useful for the targeted editing of nucleic acids, including editing a single site within the genome of a cell or subject, e.g., within the human genome. In some embodiments, fusion proteins of cas9 and nucleic acid editing enzymes or enzyme domains, e.g., deaminase domains, are provided.
President And Fellows Of Harvard College
06/18/15
20150166980

Fusions of cas9 domains and nucleic acid-editing domains


Some aspects of this disclosure provide strategies, systems, reagents, methods, and kits that are useful for the targeted editing of nucleic acids, including editing a single site within the genome of a cell or subject, e.g., within the human genome. In some embodiments, fusion proteins of cas9 and nucleic acid editing enzymes or enzyme domains, e.g., deaminase domains, are provided.
President And Fellows Of Harvard College
06/18/15
20150166678

Compositions and methods comprising binding proteins for adalimumab


Compositions and methods comprising proteins that bind specifically to adalimumab are disclosed herein. Adalimumab is a monoclonal antibody specific for the cytokine tnf-α and was developed to treat tnf-α mediated inflammatory diseases.
Abbvie Biotechnology Ltd
06/18/15
20150166628

Selective cartilage therapy


The present invention relates to compositions, methods and kits for delivery of an igf-1 protein or a functional fragment or variant, derivative thereof to cells or tissues that express proteoglycans. More specifically, the present invention relates to fusion proteins comprising a heparin binding protein (hb) comprising seq id no: 1 or seq id no: 2.
Ipsen Bioscience, Inc.
06/18/15
20150166619

Protein tag, tagged protein, and protein purification method


A protein tag comprising an amino acid sequence of the full length or a part of mafg protein or an amino acid sequence in which amino acids serving as protease cleavage sites were inserted into the former amino acid sequence is provided. Since this protein tag can impart a high insolubility attributable to mafg protein to a protein to be tagged thereby insolubilizing the tagged protein, the tagged protein can be recovered into an insoluble fraction at a high yield..
06/18/15
20150166618

Methods and compositions for treating hemophilia


Disclosed herein are methods and compositions for insertion of transgene sequences encoding proteins involved in clotting into the genome of a cell for treating conditions including hemophilias.. .
Sangamo Biosciences, Inc.
06/18/15
20150166613

Fusion proteins and combination vaccines comprising haemophilus influenzae protein e and pilin a


The present invention relates to compositions comprising haemophilus influenzae protein e and pilin a. More particularly, the present application relates to fusion proteins and immunogenic compositions comprising protein e and pila, vaccines comprising such immunogenic compositions and therapeutic uses of the same..
Glaxosmithkline Biologicals S.a.
06/18/15
20150166603

Decoy peptides inhibiting protein phosphatase 1-mediated dephosphorylation of phospholamban


The present invention relates to decoy peptide or polypeptide consisting of a peptide sequence represented by the following formula i: x1-ala-x2—x3-ile-glu-x4 (i). It is noteworthy that the decoy peptide or polypeptide of the present invention significantly elevates phosphorylation levels of plb by inhibiting pp1-mediated dephosphorylation.
Gwangju Institute Of Science And Technology
06/18/15
20150166543

Phenyl-urea and phenyl-carbamate derivatives as inhibitors of protein aggregation


The present invention relates to certain phenyl-urea and phenyl-carbamate derivatives, pharmaceutical compositions containing them, and methods of using them, including methods for preventing, reversing, slowing, or inhibiting protein aggregation, and methods of treating diseases that are associated with protein aggregation, including neurodegenerative diseases such as parkinson's disease, alzheimer's disease, lewy body disease, and multiple system atrophy.. .
Neuropore Therapies, Inc.
06/18/15
20150165054

Methods for correcting caspase-9 point mutations


Some aspects of this disclosure provide strategies, systems, reagents, methods, and kits that are useful for the targeted editing of nucleic acids, including editing a nucleic acid encoding a mutant caspase-9 protein to correct a point mutation associated with a disease or disorder, e.g., with neuroblastoma. The methods provided are useful for correcting a caspase-9 point mutation within the genome of a cell or subject, e.g., within the human genome.
President And Fellows Of Harvard College
06/18/15
20150165017

Shortened purification process for the production of capsular streptococcus pneumoniae polysaccharides


A shortened process for producing a solution containing substantially purified capsular polysaccharides from a cellular streptococcus pneumoniae lysate broth is described. Ultrafiltering and diafiltering a clarified s.
Wyeth Llc
06/18/15
20150164987

Wnt signaling inhibitor comprising insulin-like growth factor-binding protein


Provided is a novel soluble factor that modulates morphogenesis and cell proliferation, such as cardiac development and/or cardiomyocyte differentiation. Specifically provided are: an inhibitor of wnt signalling, comprising an insulin-like growth-factor-binding protein (igfbp), the protein being binding to a wnt receptor, and/or a polynucleotide encoding the protein; a medicament for prevention and/or treatment of a disease due to enhanced wnt signalling, comprising the inhibitor of wnt signalling, and a medicament for induction of cardiomyocyte differentiation; and a method for prevention and/or treatment of a disease due to enhanced wnt signalling and a method of inducing cardiomyocyte differentiation, the methods each comprising using the inhibitor of wnt signalling, and a cardiomyocyte, which is obtained by the method of inducing cardiomyocyte differentiation, and a use thereof..
National University Corporation Chiba University
06/18/15
20150164985

Method for producing a protein and lipid comprising composition with reduced digestive coagulation


The present invention relates to a process of producing a composition comprising at least two different proteins, of which at least one is a casein and at least one is an anti-coagulating protein, comprising the steps of: a) heat-sterilising a first liquid component which comprises said casein in an amount of at least 85 wt % of the total protein content of the first component, b) heat-sterilising a second liquid component comprising said anti-coagulating protein, and c) mixing said first component with said second component to obtain a mixture thereof. The obtained mixture is useful as a food constituent having reduced coagulation in the upper gastro-intestinal tract, more in particular in the stomach..
N.v. Nutricia
06/18/15
20150164968

Method of producing banana-derived composition and biologically active substance containing same


Provided is a method of producing a banana-derived composition by which a composition exhibiting excellent biological activity is obtained from a flesh part of a banana. The method includes the steps of (1) mincing a flesh part of a banana to obtain flesh fractions; (2) adding a proteolytic enzyme to the flesh fractions and decomposing proteins contained in the flesh fractions through an enzyme reaction, to obtain an enzymatic reactant; and (3) deactivating the proteolytic enzyme contained in the enzymatic reactant to obtain a composition a..
06/18/15
20150164956

Muscle-derived cells (mdcs) for treating muscle- or bone-related injury or dysfunction


The present invention provides muscle-derived cells, preferably myoblasts and muscle-derived stem cells, genetically engineered to contain and express one or more heterologous genes or functional segments of such genes, for delivery of the encoded gene products at or near sites of musculoskeletal, bone, ligament, meniscus, cartilage or genitourinary disease, injury, defect, or dysfunction. Ex vivo myoblast mediated gene delivery of human inducible nitric oxide synthase, and the resulting production of nitric oxide at and around the site of injury, are particularly provided by the invention as a treatment for lower genitourinary tract dysfunctions.
University Of Pittsburgh - Of The Commonwealth System Of Higher Education
06/18/15
20150164937

Pharmaceutical or nutraceutical composition


The invention relates to a pharmaceutical or nutraceutical composition comprising an alkalized organic substance selected from the group comprising proteins, carbohydrates, lipids, amino acids, vitamins, therapeutic agents and mixtures thereof. Such compositions are useful for treating a range of diseases and conditions.
06/11/15
20150162175

Methods for isolation and decomposition of mass spectrometric protein signatures


A method of analyzing a liquid mixture comprising protein or peptide molecules mixed with other molecules comprises: passing a portion of the mixture through a liquid chromatograph so as to elute the molecules; transferring the eluted portions of the molecules to an ion source of a mass spectrometer so as to generate ions comprising a plurality of ion species therefrom; transferring the generated ion species to a mass analyzer for detection thereby; generating a respective record of the intensity-versus-time variation of each of a plurality of the detected ion species; identifying and distinguishing a set of ion species corresponding to the ions generated from the eluted portion of the protein or peptide analyte molecules based on the records of the intensity-versus-time variation; and performing at least one additional operation on ions of one or more of the distinguished ion species generated from the protein or peptide analyte molecules.. .
Thermo Finnigan Llc
06/11/15
20150160230

Methods of predicting and decreasing the risk of pre-term birth


Provided are methods for predicting the risk of pre-term birth in a pregnant subject, for identifying a subject having an increased risk of pre-term birth, for selecting a subject for participation in a clinical study, and for decreasing the risk of pre-term birth in a subject. These methods include providing a sample from the subject and detecting the level of one or more of growth arrest-specific protein 1 (gasi), alli-fused gene from chromosome 4 protein (ar4)/fragile x mental retardation 2 (fmr2) family member 3 (aff3), transthyretin (ttr), ryanodine receptor 1 (ryri), e26 transformation specific variant 6 (etv6), claudin-10, zinc finger protein 23 (znf23), collagen type xxvii α1 (col27ai), kazrin isoform-1, keratin-associated protein 10-9 (krtapio-9), huntingtin (htt), microtubule associated protein 9 (map9), coiled-coil domain-containing protein 13 (ccdc13), inositol hexakisphosphate and diphosphoinositol-pentakisphosphate kinase isoform 2 (hisppdi), immunoglobulin gamma-3 chain c (ig-hg3), cysteine- and histidine-rich protein-1 (cyhri), and xp 002348181..
University Of Louisville Research Foundation, Inc.
06/11/15
20150160204

Methods of polypeptide identification, and compositions therefor


Methods are disclosed for identifying one or more proteins or polypeptides comprised by a sample. The methods comprise determining binding of each polypeptide with respect to each binding pool of a plurality of binding pools, wherein each binding pool comprises one or more probes which bind a structure comprised by a protein or polypeptide.
Washington University
06/11/15
20150160202

Assays for affinity profiling of nucleic acid binding proteins


Methods, compositions and kits are disclosed for assays to determine the binding affinity of dna-binding proteins or rna-binding proteins for their corresponding recognition site(s). In particular, assays are disclosed for measuring binding affinities when either the binding protein, or the recognition sequence of the recognition site, or cofactor proteins, contain one or more mutations.
Affymetrix, Inc.
06/11/15
20150160192

Antibody-binding protein-drug conjugate and methods of use


The present invention provides compositions and methods for preparing protein drug conjugate and its application to stem cell therapy and treating cancer cells. The composition is an antibody-binding-therapeutic drug conjugate that binds antibodies targeted to cancer or stem cells.
06/11/15
20150159172

Methods and compositions for genome engineering


Disclosed herein are methods and compositions for insertion of transgene sequences encoding proteins that is aberrantly expressed in disease or disorder such as a lysosomal storage disease.. .
Sangamo Biosciences, Inc.
06/11/15
20150158922

Transgenic plants expressing cobalamin binding proteins


The present invention relates to the use of transgenic plants for the expression of vitamin b12 (cobalamin) binding proteins. Plant cells are transformed with nucleotide sequences adapted for expression and secretion of vitamin b12 binding proteins.
Xeragenx Llc
06/11/15
20150158920

Transgenic plants expressing cobalamin binding proteins


The present invention relates to the use of transgenic plants for the expression of vitamin b12 (cobalamin) binding proteins. Plant cells are transformed with nucleotide sequences adapted for expression and secretion of vitamin b12 binding proteins.
Xeragenx Llc
06/11/15
20150158811

Photoreactive synthetic regulator of protein function and methods of use thereof


The present disclosure provides a photoreactive synthetic regulator of protein function. The present disclosure further provides a light-regulated polypeptide that includes a subject synthetic regulator.
The Regents Of The University Of California
06/11/15
20150157731

Transgenic plants expressing cobalamin binding proteins


The present invention relates to the use of transgenic plants for the expression of vitamin b12 (cobalamin) binding proteins. Plant cells are transformed with nucleotide sequences adapted for expression and secretion of vitamin b12 binding proteins.
Xeragenx Llc
06/04/15
20150153358

Materials and methods for diagnosing and treating shellfish allergy


The disclosure provides materials and methods for diagnosing, treating and preventing shellfish allergic reactions, including allergic reactions to shrimp. The technology involves one or more shellfish-specific proteins selected from the group of myosin light chain, sarcoplasmic calcium-binding protein, hemocyanin, fatty acid binding protein, and troponin c, for example from shrimp, as well as encoding polynucleotides, vectors host cells, and specific binding partners for such proteins, e.g., antibodies.
Icahn School Of Medicine At Mount Sinai
06/04/15
20150153327

Endogenous and non-endogenous versions of human g protein-coupled receptors


The invention disclosed in this patent document relates to transmembrane receptors, more particularly to a human g protein-coupled receptor for which the endogenous ligand is unknown (“orphan gpcr receptors”), and most particularly to mutated (non-endogenous) versions of the human gpcrs for evidence of constitutive activity.. .
Arena Pharmaceuticals, Inc.
06/04/15
20150152492

Hairpin loop double strand polynucleotide sequencing using transmembrane pores


The invention relates to a new method of sequencing a double stranded target polynucleotide. The two strands of the double stranded target polynucleotide are linked by a bridging moiety.
Oxford Nanopore Technologies Limited
06/04/15
20150152404

Proteases producing an altered immunological response and methods of making and using the same


The present invention provides novel protein variants that exhibit reduced immunogenic responses, as compared to the parental proteins. The present invention further provides dna molecules that encode novel variants, host cells comprising dna encoding novel variants, as well as methods for making proteins less allergenic.
Danisco Us Inc.
06/04/15
20150152194

Dual receptor antagonistic antigen-binding proteins and uses thereof


This disclosure relates to antagonistic dual receptor antigen-binding proteins, e.g. Antibodies and methods of using the dual receptor antibodies for treatment of pathological diseases.
Amgen Inc.
06/04/15
20150152191

Dosing regimens for use with pcsk9 inhibitors


The present invention provides methods for treating a pcsk9-mediated disease or a pcsk9-mediated condition. Specifically, the invention relates to methods comprising the administration of a proprotein convertase subtilisin/kexin type 9 (pcsk9) antibody or antigen binding protein, in the absence of a statin, to a subject in need thereof..
Regeneron Pharmaceuticals, Inc.
06/04/15
20150152175

Therapies for cancer using rlip76


The present invention is a composition identified as a region of rala binding protein 1, wherein the region neighbors a membrane-associated portion of the rala binding protein 1, reduces transport activity and membrane association of the rala binding protein 1 and kills cells undergoing uncontrolled cell growth in a subject that has cells undergoing uncontrolled cell growth. The region is used to generate medicines that kill malignant cells and tumorigenic cells.
Board Of Regents, The University Of Texas System
06/04/15
20150152169

Inhibitors of thioredoxin-interacting protein (txnip) for therapy


Described is a compound capable of reducing or inhibiting (a) the biological activity of thioredoxin-interacting protein (txnip) or (b) the expression of the gene encoding txnip for treating a condition where improving the resistance towards oxidative stress has a beneficial effect, e.g., for improving female fertiliy or extending healthy lifespan.. .
Deutsches Krebsforschungszentrum Stiftung Des Öffentlichen Rechtes


Popular terms: [SEARCH]

G Protein topics: Antibodies, Nucleic Acid, G Proteins, Nucleic Acids, Amino Acid, Polypeptide, Protein A Affinity Chromatography, Chromatography, Chromatograph, Liver Metastasis, Membrane Protein, Colorectal Carcinoma, Rectal Carcinoma, Prophylactic, Glycoprotein

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to G Protein for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for G Protein with additional patents listed. Browse our RSS directory or Search for other possible listings.
     SHARE
  
         





0.2979

3499

4 - 0 - 77